DISCONTINUED OPERATIONS	6 Months Ended
Jun. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS The Company determined that the sale of the MST Franchise represented a strategic shift that had a major effect on the business and therefore the MST Franchise met the criteria for classification as discontinued operations. Accordingly, the MST Franchise is reported as discontinued operations in accordance with ASC 205-20, Discontinued Operations ("ASC 205-20"). In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. Historically, research and development, marketing, and general and administrative expenses in discontinued operations included corporate costs incurred directly to solely support the MST Franchise. On June 11, 2026, LEO Pharma notified the Company of its decision to terminate the Finacea license agreement effective December 31, 2026. As a result, the Company does not expect to recognize Finacea royalty revenue for periods after December 31, 2026. During both the three and six months ended June 30, 2026, the Company recognized a $0.1 million loss from discontinued operations, net of income taxes, related to an uncollected receivable from transition service agreements. For the three and six months ended June 30, 2025, the loss from discontinued operations, net of income taxes was $8 thousand and $16 thousand, respectively, and consisted solely of general and administrative expenses. For the six months ended June 30, 2026, there were $0.1 million of non-cash transactions related to uncollectible receivable. There were no non-cash items related to discontinued operations for the six months ended June 30, 2025. The milestone payments for sales of ZILXI, AMZEEQ and FCD105 represent contingent consideration. Contingent consideration has been accounted for as a gain contingency in accordance with ASC 450, Contingencies, and will be recognized in earnings in the period when realizable.

DISCONTINUED OPERATIONS

6 Months Ended

Jun. 30, 2026

Discontinued Operations and Disposal Groups [Abstract]

The Company determined that the sale of the MST Franchise represented a strategic shift that had a major effect on the business and therefore the MST Franchise met the criteria for classification as discontinued operations. Accordingly, the MST Franchise is reported as discontinued operations in accordance with ASC 205-20, Discontinued Operations ("ASC 205-20"). In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. Historically, research and development, marketing, and general and administrative expenses in discontinued operations included corporate costs incurred directly to solely support the MST Franchise.

On June 11, 2026, LEO Pharma notified the Company of its decision to terminate the Finacea license agreement effective December 31, 2026. As a result, the Company does not expect to recognize Finacea royalty revenue for periods after December 31, 2026. During both the three and six months ended June 30, 2026, the Company recognized a $0.1 million loss from discontinued operations, net of income taxes, related to an uncollected receivable from transition service agreements. For the three and six months ended June 30, 2025, the loss from discontinued operations, net of income taxes was $8 thousand and $16 thousand, respectively, and consisted solely of general and administrative expenses.

For the six months ended June 30, 2026, there were $0.1 million of non-cash transactions related to uncollectible receivable. There were no non-cash items related to discontinued operations for the six months ended June 30, 2025.

The milestone payments for sales of ZILXI, AMZEEQ and FCD105 represent contingent consideration. Contingent consideration has been accounted for as a gain contingency in accordance with ASC 450, Contingencies, and will be recognized in earnings in the period when realizable.